## FILING RECEIPT PLEASE DATE STAMP AND RETURN TO US - BOX 235X

In re application of

Tatsuki SHIOTA, et al.

Appln. No. 10/031,698

Confirmation No.: 8252.

Filed: January 23, 2002

For: CYCLIC AMINE CCR3 ANTAGONIST

PAPERS FILED:

1. INFORMATION DISCLOSURE STATEMENT (with 7 references and PTO/SB/08 A & B (modified) (substitute for PTO Form 1449))

SUGHRUE MION, PLLC

2100 Pennsylvania Avenue, N.W.

Washington, D.C. 20037-3213 Telephone: (202) 293-7060

Facsimile: (202) 293-7860

DOCKET NO.: Q68142 ATTORNEY/SEC: JJR/rg

Group Art Unit: NOT YET ASSIGNED

**Examiner: NOT YET ASSIGNED** 

Date Filed: April 23, 2002





## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Tatsuki SHIOTA, et al.

Appln. No. 10/031,698

Group Art Unit: NOT YET ASSIGNED

Confirmation No.: 8252

Examiner: NOT YET ASSIGNED

Filed: January 23, 2002

For:

CYCLIC AMINE CCR3 ANTAGONIST

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) (substitute for PTO Form 1449) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date for an application other than a continued prosecution application (CPA) under §1.53(d); (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/031,698

request for continued examination (RCE) under §1.114, and therefore, no Statement under

37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Complete English translations of foreign language documents are being submitted

herewith, and therefore no concise explanation for such foreign language documents is required.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

Respectfully submitted,

Registration No. 44,820

SUGHRUE MION, PLLC

2100 Pennsylvania Avenue, N.W.

Washington, D.C. 20037-3213 Telephone: (202) 293-7060

Facsimile: (202) 293-7860

Date: April 23, 2002

2

Complete if Known

10/031,698

00 0000	
January 23, 2002	
tsuki SHIOTA	
OT YET ASSIGNED	
OT YET ASSIGNED	
58142	
(	

**Application Number** 

U.S. PATENT DOCUMENTS						
Examiner	Cite No.1	Document :	Number	Bublication Date		
Initials*		Number	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US			•	
		US				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	
	No.1	Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY Applicant of Cited Document	Translation <sup>6</sup>	
		EP	0217286	A1	04-08-87		
		wo	98/50534	A1	11-12-98		
		WO	97/40051	A1	10-30-97		
		wo	00/31032	A1	06-02-00		
		wo	99/25686	A1	05-27-99	,	
		GB	2106108	Α	04-07-83	-	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>	
		"N,N'-Disubstituted L-Isoglutamnes As Novel Cancer Chemotherapeutic Agents", Khalid M. Burzynski S.R., DRUGS EXPTL. CLIN. RES., SUPPL. Vol. 1, XIII, pgs. 57-60 (1987)		

Examiner Signature	Date Considered	d

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.